Molecular targeted therapy for anticancer treatment

참고문헌 (257)

1. Sung, H., "Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J. Clin, 71, pp.209~249 (2021)
2. Ke, X., "Molecular targeted therapy of cancer : the progress and future prospect", Front. Lab. Med, 1, pp.69~75 (2017)
3. Jemal, A., "Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control", J. Natl Cancer Inst, 100, pp.1672~1694 (2008)
4. Saini, K. S., "Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework", Br. J. Cancer, 125, pp.155~163 (2021)
5. Usborne, C. M., "A review of systemic anticancer therapy in disease palliation", Br. Med. Bull, 125, pp.43~53 (2017)
6. Lind, M. J., "Principles of systemic anticancer therapy", Medicine, 44, pp.20~24 (2016)
7. Jones, R., "Cytotoxic chemotherapy : clinical aspects", Medicine, 44, pp.25~29 (2016)
8. Zhong, L., "Small molecules in targeted cancer therapy : advances, challenges, and future perspectives", Signal Transduct. Target. Ther, 6, pp.201~ (2021)
9. Charlton, P., "Targeted therapy in cancer", Medicine, 44, pp.34~38 (2016)
10. Peters, G. J., "From ‘targeted therapy’ to targeted therapy", Anticancer Res, 39, pp.3341~3345 (2019)
11. Abraham, J., "Hormonal therapy for cancer", Medicine, 44, pp.30~33 (2016)
12. Waldman, A. D., "A guide to cancer immunotherapy : from T cell basic science to clinical practice", Nat. Rev. Immunol, 20, pp.651~658 (2020)
13. Keefe, D. M. K., "Potential successes and challenges of targeted cancer therapies", J. Natl Cancer Inst. Monogr, pp.lgz008~ (2019)
14. Lee, Y. T., "Molecular targeted therapy : treating cancer with specificity", Eur. J. Pharmacol, 834, pp.188~196 (2018)
15. Habeeb, N. W.-A., "The use of targeted therapies for precision medicine in oncology", Clin. Chem, 62, pp.1556~1564 (2016)
16. Valent, P., "Paul Ehrlich(1854–1915)and his contributions to the foundation and birth of translational medicine", J. Innate Immun, 8, pp.111~120 (2016)
17. Colomer, R., "When should we order a next generation sequencing test in a patient with cancer?", EClinicalMedicine, 25, pp.100487~ (2020)
18. Dillman, R. O., "Perceptions of Herceptin : a monoclonal antibody for the treatment of breast cancer", Cancer Biother. Radiopharm, 14, pp.5~10 (1999)
19. Cohen, M. H., "Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia", Clin. Cancer Res, 8, pp.935~942 (2002)
20. Zahavi, D., "Monoclonal antibodies in cancer therapy", Antibodies, 9, pp.34~ (2020)
21. Bhullar, K. S., "Kinase-targeted cancer therapies: progress, challenges and future directions", Mol. Cancer, 17, pp.48~ (2018)
22. Hanahan, D., "Hallmarks of cancer : the next generation", Cell, 144, pp.646~674 (2011)
23. Cohen, P., "Kinase drug discovery 20 years after imatinib : progress and future directions", Nat. Rev. Drug Discov, 20, pp.551~569 (2021)
24. Du, Z., "Mechanisms of receptor tyrosine kinase activation in cancer", Mol. Cancer, 17, pp.58~ (2018)
25. Lemmon, M. A., "Cell signaling by receptor tyrosine kinases", Cell, 141, pp.1117~1134 (2010)
26. Roskoski, R. Jr., "Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes", Pharmacol. Res, 103, pp.26~48 (2016)
27. Lu, X., "New promise and opportunities for allosteric kinase inhibitors", Angew. Chem. Int. Ed. Engl, 59, pp.13764~13776 (2020)
28. Okamoto, K., "Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization", ACS Med. Chem. Lett, 6, pp.89~94 (2015)
29. Li, J. Y., "Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades", Mol. Cancer, 20, pp.27~ (2021)
30. Kersh, A. E., "Targeted therapies: immunologic effects and potential applications outside of cancer", J. Clin. Pharmacol, 58, pp.7~24 (2018)
31. Joly, E., "What is trogocytosis and what is its purpose?", Nat. Immunol, 4, pp.815~ (2003)
32. Miyake, K., "The role of trogocytosis in the modulation of immune cell functions", Cells, 10, pp.1255~ (2021)
33. Matlung, H. L., "Neutrophils kill antibody-opsonized cancer cells by trogoptosis", Cell Rep, 23, pp.3946~3959 (2018)
34. Hsu, Y. F., "Complement activation mediates cetuximab inhibition of nonsmall cell lung cancer tumor growth in vivo", Mol. Cancer, 9, pp.139~ (2010)
35. Lizotte, P. H., "A high-throughput immune-oncology screen identifies EGFR inhibitors as potent enhancers of antigen-specific cytotoxic T-lymphocyte tumor cell killing", Cancer Immunol. Res, 6, pp.1511~1523 (2018)
36. Donia, M., "BRAF inhibition improves tumor recognition by the immune system : potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer", Oncoimmunology, 1, pp.1476~1483 (2012)
37. Ayeni, D., "Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors", J. Immunother. Cancer, 7, pp.172~ (2019)
38. Ellis, L. M., "Resistance to targeted therapies : refining anticancer therapy in the era of molecular oncology", Clin. Cancer Res, 15, pp.7471~7478 (2009)
39. Hou, J., "Evolution of molecular targeted cancer therapy : mechanisms of drug resistance and novel opportunities identified by CRISPR-Cas9 screening", Front. Oncol, 12, pp.755053~ (2022)
40. Rebecca, V. W., "Nongenetic mechanisms of drug resistance in melanoma", Annu. Rev. Cancer Biol, 4, pp.315~330 (2020)
41. Marusyk, A., "Intratumor heterogeneity : the rosetta stone of therapy resistance", Cancer Cell, 37, pp.471~484 (2020)
42. Turner, N. C., "Genetic heterogeneity and cancer drug resistance", Lancet Oncol, 13, pp.e178~e185 (2012)
43. Meador, C. B., "Acquired resistance to targeted therapies in NSCLC : updates and evolving insights", Pharmacol. Ther, 210, pp.107522~ (2020)
44. Li, X., "The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine", Biomed. Pharmacother, 150, pp.113064~ (2022)
45. Wheeler, D. L., "Understanding resistance to EGFR inhibitors-impact on future treatment strategies", Nat. Rev. Clin. Oncol, 7, pp.493~507 (2010)
46. Ni, Y., "The role of tumor-stroma interactions in drug resistance within tumor microenvironment", Front. Cell Dev. Biol, 9, pp.637675~ (2021)
47. Liu, Y., "E3 ubiquitin ligase in anticancer drugdsla resistance : recent advances and future potential", Front. Pharmacol, 12, pp.645864~ (2021)
48. Qin, S., "Emerging role of tumor cell plasticity in modifying therapeutic response", Signal Transduct. Target. Ther, 5, pp.228~ (2020)
49. Roger, S., "Adverse events of targeted therapies reported by patients with cancer treated in primary care", Eur. J. Gen. Pract, 26, pp.202~209 (2020)
50. Widakowich, C., "Review : side effects of approved molecular targeted therapies in solid cancers", Oncologist, 12, pp.1443~1455 (2007)
51. Fabbrocini, G., "Acneiform rash induced by EGFR inhibitors : review of the literature and new insights", Ski. Appendage Disord, 1, pp.31~37 (2015)
52. Liu, S., "Toxicity of targeted therapy : implications for response and impact of genetic polymorphisms", Cancer Treat. Rev, 40, pp.883~891 (2014)
53. Assoun, S., "Molecular targeted therapy-related lifethreatening toxicity in patients with malignancies. A systematic review of published cases", Intensive Care Med, 45, pp.988~997 (2019)
54. Roskoski, R. Jr., "The ErbB", HER family of protein-tyrosine kinases and cancer, 2014, pp.79, 34~74
55. Scaltriti, M., "The epidermal growth factor receptor pathway : a model for targeted therapy", Clin. Cancer Res, 12, pp.5268~5272 (2006)
56. Dean-Colomb, W., "Her2-positive breast cancer : herceptin and beyond", Eur. J. Cancer, 44, pp.2806~2812 (2008)
57. Pirker, R., "Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop", J. Thorac. Oncol, 5, pp.1706~1713 (2010)
58. Thomas, R., "Rethink of EGFR in cancer with its kinase independent function on board", Front. Oncol, 9, pp.800~ (2019)
59. Guo, G., "Ligand-independent EGFR signaling", Cancer Res, 75, pp.3436~3441 (2015)
60. Wee, P., "Epidermal growth factor receptor cell proliferation signaling pathways", Cancers, 9, pp.52~ (2017)
61. Ha, S. Y., "Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR", Oncotarget, 6, pp.5465~5474 (2015)
62. Amelia, T., "Structural insight and development of EGFR tyrosine kinase inhibitors", Molecules, 27, pp.819~ (2022)
63. Giaccone, G., "The role of gefitinib in lung cancer treatment", Clin. Cancer Res, 10, pp.4233s~4237s (2004)
64. Johnson, J. R., "Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen", Clin. Cancer Res, 11, pp.6414~6421 (2005)
65. Li, D., "BIBW2992, an irreversible EGFR", HER2 inhibitor highly effective in preclinical lung cancer models, 2008, pp.27, 4702~4711
66. Lau, S. C. M., "Dacomitinib in the management of advanced non-small-cell lung cancer", Drugs, 79, pp.823~831 (2019)
67. Kobayashi, Y., "EGFR T790M and C797S mutations as mechanisms of acquired resistance to dacomitinib", J. Thorac. Oncol, 13, pp.727~731 (2018)
68. Sharma, S. V., "Epidermal growth factor receptor mutations in lung cancer", Nat. Rev. Cancer, 7, pp.169~181 (2007)
69. Suda, K., "EGFR T790M mutation: a double role in lung cancer cell survival?", J. Thorac. Oncol, 4, pp.1~4 (2009)
70. Cross, D. A., "AZD9291, an irreversible EGFR TKI, overcomes T790Mmediated resistance to EGFR inhibitors in lung cancer", Cancer Disco, 4, pp.1046~1061 (2014)
71. Santarpia, M., "Osimertinib in the treatment of non-small-cell lung cancer : design, development and place in therapy", Lung Cancer, 8, pp.109~125 (2017)
72. Dhillon, S., "Lazertinib : first approval", Drugs, 81, pp.1107~1113 (2021)
73. Shah, R. R., "Safety and tolerability of epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors in oncology", Drug Saf, 42, pp.181~198 (2019)
74. Duggirala Krishna Babu, "Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations", Biomolecules & Therapeutics, 30(1), pp.19~27 (2022), 한국응용약물학회[DOI]
75. Leonetti, A., "Resistance mechanisms to osimertinib in EGFR-mutated nonsmall cell lung cancer", Br. J. Cancer, 121, pp.725~737 (2019)
76. Wang, S., "EAI045 : The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance", Cancer Lett, 385, pp.51~54 (2017)
77. Schalm, S. S., "1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M", C797S resistant NSCLC, 2020, pp.31, S839~
78. Kim, D. S., "Abstract 5350 : OBX02-011, a reversible fourth-generation EGFRTKI, overcomes C797S-mediated resistance in non-small cell lung cancer", Cancer Res, 82, pp.5350~ (2022)
79. Joel Rivera-Concepcion, "Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer", Cancer Research and Treatment, 54(2), pp.315~329 (2022), 대한암학회[DOI]
80. Kohler, J., "Amivantamab : treating EGFR Exon 20-mutant cancers with bispecific antibody-mediated receptor degradation", J. Clin. Oncol, 39, pp.3403~3406 (2021)
81. Pacheco, J. M., "Mobocertinib : a potential treatment for NSCLC with EGFR Exon 20insertions", Cancer Disco, 11, pp.1617~1619 (2021)
82. Rusnak, D., "The discovery of lapatinib(GW572016)", Mol. Cancer Ther, 10, pp.2019~ (2011)
83. Tsang, R. Y., "Lapatinib, a dual-targeted small molecule inhibitor of EGFR and HER2, in HER2-amplified breast cancer: from bench to bedside", Clin. Med. Insights: Ther, 3, pp.CMT.S3783~ (2011)
84. Martin, M., "Emerging therapeutic options for HER2-positive breast cancer", Am. Soc. Clin. Oncol. Educ. Book, pp.e64~e70 (2016)
85. Kulukian, A., "Preclinical activity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models", Mol. Cancer Ther, 19, pp.976~987 (2020)
86. Chow, L. W. C., "Advances in EGFR", HER2-directed clinical research on breast cancer, 2020, pp.147, 375~428
87. Galizia, G., "Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer", Oncogene, 26, pp.3654~3660 (2007)
88. Li, Q. H., "Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance", Gastroenterol. Rep, 8, pp.179~191 (2020)
89. Keating, G. M., "Panitumumab : a review of its use in metastatic colorectal cancer", Drugs, 70, pp.1059~1078 (2010)
90. Nami, B., "Mechanisms underlying the action and synergism of trastuzumab and pertuzumab in targeting HER2-positive breast cancer", Cancers, 10, pp.342~ (2018)
91. Cho, S. M., "Timeline of FDAapproved targeted therapy for cholangiocarcinoma", Cancers, 14, pp.2641~ (2022)
92. Della Corte, C. M., "Role and targeting of anaplastic lymphoma kinase in cancer", Mol. Cancer, 17, pp.30~ (2018)
93. Webb, T. R., "Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy", Expert Rev. Anticancer Ther, 9, pp.331~356 (2009)
94. Takeuchi, K., "Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts", Clin. Cancer Res, 14, pp.6618~6624 (2008)
95. Katayama, R., "Therapeutic targeting of anaplastic lymphoma kinase in lung cancer : a paradigm for precision cancer medicine", Clin. Cancer Res, 21, pp.2227~2235 (2015)
96. Golding, B., "The function and therapeutic targeting of anaplastic lymphoma kinase(ALK)in non-small cell lung cancer(NSCLC)", Mol. Cancer, 17, pp.52~ (2018)
97. Zou, H. Y., "An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms", Cancer Res, 67, pp.4408~4417 (2007)
98. Shaw, A. T., "Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer(NSCLC) : updated results, including overall survival, from PROFILE 1001", Ann. Oncol, 30, pp.1121~1126 (2019)
99. Hong, L., "Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer", Ther. Adv. Med. Oncol, 13, pp.1758835921992976~ (2021)
100. Ernani, V., "Management of brain metastases in non–smallcell lung cancer", JCO Oncol. Pract, 15, pp.563~570 (2019)
101. Naito, T., "Brigatinib and lorlatinib : their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases", Jpn. J. Clin. Oncol, 51, pp.37~44 (2021)
102. Zhang, S., "The potent ALK inhibitor Brigatinib(AP26113)overcomes mechanisms of resistance to first-and second-generation ALK inhibitors in preclinical models", Clin. Cancer Res, 22, pp.5527~5538 (2016)
103. Eder, J. P., "Novel therapeutic inhibitors of the c-Met signaling pathway in cancer", Clin. Cancer Res, 15, pp.2207~2214 (2009)
104. Turke, A. B., "Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC", Cancer Cell, 17, pp.77~88 (2010)
105. Frampton, G. M., "Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors", Cancer Disco, 5, pp.850~859 (2015)
106. Cocco, E., "NTRK fusion-positive cancers and TRK inhibitor therapy", Nat. Rev. Clin. Oncol, 15, pp.731~747 (2018)
107. Laetsch, T. W., "Tropomyosin receptor kinase inhibitors for the treatment of TRK fusion cancer", Clin. Cancer Res, 27, pp.4974~4982 (2021)
108. Kazi, J. U., "FMS-like tyrosine kinase 3", FLT3 : from basic science to clinical implications, 2019, pp.99, 1433~1466
109. Perl, A. E., "Availability of FLT3 inhibitors: how do we use them?", Blood, 134, pp.741~745 (2019)
110. Kohlmann, A., "Gene expression profiling in AML with normal karyotype can predict mutations for molecular markers and allows novel insights into perturbed biological pathways", Leukemia, 24, pp.1216~1220 (2010)
111. Crook, T., "Angiogenesis inhibitors in personalized combination regimens for the treatment of advanced refractory cancers", Front. Mol. Med, 1, pp.749283~ (2021)
112. Chen, P. H., "Platelet-derived growth factors and their receptors:structural and functional perspectives", Biochim. Biophys. Acta, 1834, pp.2176~2186 (2013)
113. Andrae, J., "Role of platelet-derived growth factors in physiology and medicine", Genes Dev, 22, pp.1276~1312 (2008)
114. Heldin, C. H., "Targeting the PDGF signaling pathway in tumor treatment", Cell Commun. Signal, 11, pp.97~ (2013)
115. Ellis, L. M., "VEGF-targeted therapy : mechanisms of anti-tumour activity", Nat. Rev. Cancer, 8, pp.579~591 (2008)
116. Harper, S. J., "VEGF-A splicing : the key to anti-angiogenic therapeutics?", Nat. Rev. Cancer, 8, pp.880~887 (2008)
117. El-Kenawi, A. E., "Angiogenesis inhibitors in cancer therapy : mechanistic perspective on classification and treatment rationales", Br. J. Pharmacol, 170, pp.712~729 (2013)
118. Scavelli, C., "Crosstalk between angiogenesis and lymphangiogenesis in tumor progression", Leukemia, 18, pp.1054~1058 (2004)
119. Liang, Y., "Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones", Endocr. Relat. Cancer, 13, pp.905~919 (2006)
120. Kong, D., "VEGF-C mediates tumor growth and metastasis through promoting EMT-epithelial breast cancer cell crosstalk", Oncogene, 40, pp.964~979 (2021)
121. Zhao, D., "VEGF drives cancer-initiating stem cells through VEGFR-2", Stat3 signaling to upregulate Myc and Sox2, 2015, pp.34, 3107~3119
122. Kaplan, R. N., "VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche", Nature, 438, pp.820~827 (2005)
123. Beenken, A., "The FGF family : biology, pathophysiology and therapy", Nat. Rev. Drug Discov, 8, pp.235~253 (2009)
124. Babina, I. S., "Advances and challenges in targeting FGFR signalling in cancer", Nat. Rev. Cancer, 17, pp.318~332 (2017)
125. Regeenes, R., "Fibroblast growth factor receptor 5(FGFR5)is a co-receptor for FGFR1 that is up-regulated in beta-cells by cytokine-induced inflammation", J. Biol. Chem, 293, pp.17218~17228 (2018)
126. Xie, Y., "FGF", FGFR signaling in health and disease, 2020, pp.5, 181~
127. Liang, J., "The C-kit receptor-mediated signal transduction and tumorrelated diseases", Int. J. Biol. Sci, 9, pp.435~443 (2013)
128. Salvatore, D., "The importance of the RET gene in thyroid cancer and therapeutic implications", Nat. Rev. Endocrinol, 17, pp.296~306 (2021)
129. Jones, N., "Tie receptors: new modulators of angiogenic and lymphangiogenic responses", Nat. Rev. Mol. Cell. Biol, 2, pp.257~267 (2001)
130. Hume, D. A., "Therapeutic applications of macrophage colonystimulating factor-1(CSF-1)and antagonists of CSF-1 receptor(CSF-1R)signaling", Blood, 119, pp.1810~1820 (2012)
131. Soares, M. J., "CSF1R copy number changes, point mutations, and RNA and protein overexpression in renal cell carcinomas", Mod. Pathol, 22, pp.744~752 (2009)
132. Yang, X. H., "Overexpression of the receptor tyrosine kinase Tie-1 intracellular domain in breast cancer", Tumor Biol, 24, pp.61~69 (2003)
133. Roskoski, R., "The role of fibroblast growth factor receptor (FGFR) proteintyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder", Pharmacol. Res, 151, pp.104567~ (2020)
134. Yamaoka, T., "Receptor tyrosine kinase-targeted cancer therapy", Int. J. Mol. Sci, 19, pp.3491~ (2018)
135. Greuber, E. K., "Role of ABL family kinases in cancer : from leukaemia to solid tumours", Nat. Rev. Cancer, 13, pp.559~571 (2013)
136. Colicelli, J., "ABL tyrosine kinases: evolution of function, regulation, and specificity", Sci. Signal, 3, pp.re6~ (2010)
137. Rossari, F., "Past, present, and future of Bcr-Abl inhibitors : from chemical development to clinical efficacy", J. Hematol. Oncol, 11, pp.84~ (2018)
138. Giles, F. J., "Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia", Leukemia, 23, pp.1698~1707 (2009)
139. Weisberg, E., "AMN107(nilotinib) : a novel and selective inhibitor of BCR-ABL", Br. J. Cancer, 94, pp.1765~1769 (2006)
140. Puttini, M., "In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells", Cancer Res, 66, pp.11314~11322 (2006)
141. Hochhaus, A., "Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann. Oncol, 28, pp.iv41~iv51 (2017)
142. Eskazan, A. E., "Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update", Ther. Adv. Hematol, 8, pp.237~243 (2017)
143. Schoepfer, J., "Discovery of asciminib(ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1", J. Med. Chem, 61, pp.8120~8135 (2018)
144. Hughes, T. P., "Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure", N. Engl. J. Med, 381, pp.2315~2326 (2019)
145. Tan, F. H., "Ponatinib : a novel multityrosine kinase inhibitor against human malignancies", Onco. Targets Ther, 12, pp.635~645 (2019)
146. Parsons, S. J., "Src family kinases, key regulators of signal transduction", Oncogene, 23, pp.7906~7909 (2004)
147. Wheeler, D. L., "The role of Src in solid tumors", Oncologist, 14, pp.667~678 (2009)
148. Zhang, S., "Targeting Src family kinases in anti-cancer therapies : turning promise into triumph", Trends Pharmacol. Sci, 33, pp.122~128 (2012)
149. -1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor, "J. Med. Chem", 2006, 6819~6832
150. Martellucci, S., "Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned so Far", Cancers, 12, pp.1448~ (2020)
151. Wen, T., "Inhibitors targeting Bruton’s tyrosine kinase in cancers : drug development advances", Leukemia, 35, pp.312~332 (2021)
152. Pal Singh, S., "Role of Bruton’s tyrosine kinase in B cells and malignancies", Mol. Cancer, 17, pp.57~ (2018)
153. Seavey, M. M., "The many faces of Janus kinase", Biochem. Pharmacol, 83, pp.1136~1145 (2012)
154. Lee, H. J., "The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia", Clin. Cancer Res, 19, pp.327~335 (2013)
155. Quintas-Cardama, A., "Molecular pathways : Jak", STAT pathway : mutations, inhibitors, and resistance, 2013, pp.19, 1933~1940
156. Prior, I. A., "The frequency of Ras mutations in cancer", Cancer Res, 80, pp.2969~2974 (2020)
157. Yaeger, R., "Targeting alterations in the RAF-MEK pathway", Cancer Disco, 9, pp.329~341 (2019)
158. Yang, J., "Targeting PI3K in cancer : mechanisms and advances in clinical trials", Mol. Cancer, 18, pp.26~ (2019)
159. Lim, S., "Cdks, cyclins and CKIs : roles beyond cell cycle regulation", Development, 140, pp.3079~3093 (2013)
160. Otto, T., "Cell cycle proteins as promising targets in cancer therapy", Nat. Rev. Cancer, 17, pp.93~115 (2017)
161. Kwang-NymCho, "Chemistry and Biology of Ras Farnesyltransferase", Archives of Pharmacal Research, 25(6), pp.759~769 (2002), 대한약학회
162. Wang, J., "New tricks for human farnesyltransferase inhibitor : cancer and beyond", Medchemcomm, 8, pp.841~854 (2017)
163. Zhang, S. S., "Spotlight on Sotorasib(AMG 510)for KRAS(G12C)positive non-small cell lung cancer", Lung Cancer, 12, pp.115~122 (2021)
164. Blair, H. A., "Sotorasib : first approval", Drugs, 81, pp.1573~1579 (2021)
165. Janne, P. A., "Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C)mutation", N. Engl. J. Med, 387, pp.120~131 (2022)
166. Wellbrock, C., "The RAF proteins take centre stage", Nat. Rev. Mol. Cell. Biol, 5, pp.875~885 (2004)
167. Yuan, J., "The MAPK and AMPK signalings : interplay and implication in targeted cancer therapy", J. Hematol. Oncol, 13, pp.113~ (2020)
168. Koelblinger, P., "Development of encorafenib for BRAF-mutated advanced melanoma", Curr. Opin. Oncol, 30, pp.125~133 (2018)
169. Saxton, R. A., "mTOR signaling in growth, metabolism, and disease", Cell, 168, pp.960~976 (2017)
170. Liu, R., "PI3K", AKT pathway as a key link modulates the multidrug resistance of cancers, 2020, pp.11, 797~
171. Chauhan, A. F., "Copanlisib in the treatment of relapsed follicular lymphoma : utility and experience from the clinic", Cancer Manag. Res, 13, pp.677~692 (2021)
172. Cheah, C. Y., "Idelalisib in the management of lymphoma", Blood, 128, pp.331~336 (2016)
173. Lu, J., "Palbociclib : a first-in-class CDK4", CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer, 2015, pp.8, 98~
174. Hortobagyi, G. N., "Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer : a review of subgroup analyses from the MONALEESA-2 trial", Breast Cancer Res, 20, pp.123~ (2018)
175. Lord, C. J., "PARP inhibitors: Synthetic lethality in the clinic", Science, 355, pp.1152~1158 (2017)
176. Pilie, P. G., "PARP inhibitors : extending benefit beyond BRCA-mutant cancers", Clin. Cancer Res, 25, pp.3759~3771 (2019)
177. Lord, C. J., "BRCAness revisited", Nat. Rev. Cancer, 16, pp.110~120 (2016)
178. Rose, M., "PARP inhibitors:clinical relevance, mechanisms of action and tumor resistance", Front. Cell Dev. Biol, 8, pp.564601~ (2020)
179. Meng, F., "Drug design targeting active posttranslational modification protein isoforms", Med. Res. Rev, 41, pp.1701~1750 (2021)
180. Bekes, M., "PROTAC targeted protein degraders : the past is prologue", Nat. Rev. Drug Discov, 21, pp.181~200 (2022)
181. Moore, A. R., "RAS-targeted therapies:is the undruggable drugged?", Nat. Rev. Drug Discov, 19, pp.533~552 (2020)
182. Ostrem, J. M., "K-Ras(G12C)inhibitors allosterically control GTP affinity and effector interactions", Nature, 503, pp.548~551 (2013)
183. Lietman, C. D., "More to the RAS story : KRAS(G12C)inhibition, resistance mechanisms, and moving beyond KRAS(G12C)", Am. Soc. Clin. Oncol. Educ. Book, 42, pp.1~13 (2022)
184. Lim, S. M., "Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor", Angew. Chem. Int. Ed. Engl, 53, pp.199~204 (2014)
185. Wang, X., "Identification of MRTX1133, a noncovalent, potent, and selective KRAS(G12D)inhibitor", J. Med. Chem, 65, pp.3123~3133 (2022)
186. Mao, Z., "KRAS(G12D)can be targeted by potent inhibitors via formation of salt bridge", Cell Disco, 8, pp.5~ (2022)
187. McCutcheon, J. N., "Next-generation sequencing: targeting targeted therapies", Clin. Cancer Res, 21, pp.3584~3585 (2015)
188. Udagawa, C., "Pharmacogenetics for severe adverse drug reactions induced by molecular-targeted therapy", Cancer Sci, 111, pp.3445~3457 (2020)
189. Keshava, N., "Defining subpopulations of differential drug response to reveal novel target populations", NPJ Syst. Biol. Appl, 5, pp.36~ (2019)
190. Luo, Y., "Next Decade’s AI-based drug development features tight integration of data and computation", Health Data Sci, 2022, pp.9816939~ (2022)
191. Ting, N. L., "Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes", Gut, 71, pp.1412~1425 (2022)
192. Ramirez-Labrada, A. G., "The influence of lung microbiota on lung carcinogenesis, immunity, and immunotherapy", Trends Cancer, 6, pp.86~97 (2020)
193. Kadosh, E., "The gut microbiome switches mutant p53 from tumoursuppressive to oncogenic", Nature, 586, pp.133~138 (2020)
194. Gopalakrishnan, V., "Gut microbiome modulates response to anti-PD-1immunotherapy in melanoma patients", Science, 359, pp.97~103 (2018)
195. Nagano, T., "Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy", Cells, 7, pp.212~ (2018)
196. van der Wekken, A. J., "Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature", Crit. Rev. Oncol. Hematol, 100, pp.107~116 (2016)
197. Sequist, L. V., "Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors", Sci. Transl. Med, 3, pp.75ra26~ (2011)
198. Dungo, R. T., "Afatinib : first global approval", Drugs, 73, pp.1503~1515 (2013)
199. Zhang, Y., "The efficacy and toxicity of afatinib in advanced EGFR-positive non-small-cell lung cancer patients after failure of first-generation tyrosine kinase inhibitors : a systematic review and meta-analysis", J. Thorac. Dis, 9, pp.1980~1987 (2017)
200. Shirley, M., "Dacomitinib : first global approval", Drugs, 78, pp.1947~1953 (2018)
201. Reungwetwattana, T., "Dacomitinib as firstline treatment for EGFR mutation-positive non-small cell lung cancer", Expert Rev. Precis. Med. Drug Dev, 6, pp.161~171 (2021)
202. Greig, S. L., "Osimertinib : first global approval", Drugs, 76, pp.263~273 (2016)
203. Cooper, A. J., "Third-generation EGFR and ALK inhibitors : mechanisms of resistance and management", Nat. Rev. Clin. Oncol, 19, pp.499~514 (2022)
204. Vogel, W. H., "Management strategies for adverse events associated with EGFR TKIs in non-small cell lung cancer", J. Adv. Pract. Oncol, 7, pp.723~735 (2016)
205. "Cetuximab approved by FDA for treatment of head and neck squamous cell cancer", Cancer Biol. Ther, 5, pp.340~342 (2006)
206. Peeters, M., "Panitumumab in metastatic colorectal cancer : the importance of tumour RAS status", Drugs, 75, pp.731~748 (2015)
207. Thomas, M., "Cetuximab : adverse event profile and recommendations for toxicity management", Clin. J. Oncol. Nurs, 9, pp.332~338 (2005)
208. Zhao, B., "Mechanisms of resistance to anti-EGFR therapy in colorectal cancer", Oncotarget, 8, pp.3980~4000 (2017)
209. Boekhout, A. H., "Trastuzumab", Oncologist, 16, pp.800~810 (2011)
210. Howie, L. J., "FDA approval summary : pertuzumab for adjuvant treatment of HER2-positive early breast cancer", Clin. Cancer Res, 25, pp.2949~2955 (2019)
211. Schlam, I., "HER2-positive breast cancer and tyrosine kinase inhibitors : the time is now", NPJ Breast Cancer, 7, pp.56~ (2021)
212. Sudhan, D. R., "Hyperactivation of TORC1 drives resistance to the Pan-HER tyrosine kinase inhibitor neratinib in HER2-mutant cancers", Cancer Cell, 37, pp.183~199 (2020)
213. Recondo, G., "Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or nextgeneration TKI?", Nat. Rev. Clin. Oncol, 15, pp.694~708 (2018)
214. Fujino, T., "Foretinib can overcome common on-target resistance mutations after capmatinib", tepotinib treatment in NSCLCs with MET exon 14 skipping mutation, 2022, pp.15, 79~
215. Cerchione, C., "Safety of FLT3 inhibitors in patients with acute myeloid leukemia", Expert Rev. Hematol, 14, pp.851~865 (2021)
216. Desikan, S. P., "Resistance to targeted therapies : delving into FLT3 and IDH", Blood Cancer J, 12, pp.91~ (2022)
217. Friedman, R., "The molecular mechanisms behind activation of FLT3 in acute myeloid leukemia and resistance to therapy by selective inhibitors", Biochim. Biophys. Acta Rev. Cancer, 1877, pp.188666~ (2022)
218. Goodman, V. L., "Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma", Clin. Cancer Res, 13, pp.1367~1373 (2007)
219. Joosten, S. C., "Resistance to sunitinib in renal cell carcinoma: from molecular mechanisms to predictive markers and future perspectives", Biochim. Biophys. Acta, 1855, pp.1~16 (2015)
220. Qin, S., "Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy", J. Hematol. Oncol, 12, pp.27~ (2019)
221. Fallahi, P., "Selective use of vandetanib in the treatment of thyroid cancer", Drug Des. Devel. Ther, 9, pp.3459~3470 (2015)
222. Bauer, S., "Early and next-generation KIT", PDGFRA kinase inhibitors and the future of treatment for advanced gastrointestinal stromal tumor, 2021, pp.11, 672500~
223. Cowey, C. L., "Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma", Drug Des. Devel. Ther, 7, pp.519~527 (2013)
224. Kommalapati, A., "FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice", Cancers, 13, pp.2968~ (2021)
225. Yue, S., "FGFR-TKI resistance in cancer : current status and perspectives", J. Hematol., Oncol, 14, pp.23~ (2021)
226. Jiang, K., "GZD824 overcomes FGFR1-V561F", M mutant resistance in vitro and in vivo, 2021, pp.10, 4874~4884
227. Thein, K. Z., "Precision therapy for RET-altered cancers with RET inhibitors", Trends Cancer, 7, pp.1074~1088 (2021)
228. Lin, J. J., "An early look at selective RET inhibitor resistance : new challenges and opportunities", Br. J. Cancer, 124, pp.1757~1758 (2021)
229. Garcia, J., "Bevacizumab(Avastin(R))in cancer treatment : a review of 15years of clinical experience and future outlook", Cancer Treat. Rev, 86, pp.102017~ (2020)
230. Young, K., "Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma", Ther. Adv. Gastroenterol, 8, pp.373~383 (2015)
231. Ha, D., "Pattern of adverse events induced by aflibercept and ranibizumab : a nationwide spontaneous adverse event reporting database, 2007–2016", Medicine, 98, pp.e16785~ (2019)
232. Braun, T. P., "Response and resistance to BCR-ABL1-targeted therapies", Cancer Cell, 37, pp.530~542 (2020)
233. Conchon, M., "Dasatinib-clinical trials and management of adverse events in imatinib resistant", intolerant chronic myeloid leukemia, 2011, pp.33, 131~139
234. Kim, S. H., "Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors", Haematologica, 99, pp.1191~1196 (2014)
235. Lipsky, A., "Managing toxicities of Bruton tyrosine kinase inhibitors", Hematol. Am. Soc. Hematol. Educ. Program, 2020, pp.336~345 (2020)
236. Estupinan, H. Y., "BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib", Leukemia, 35, pp.1317~1329 (2021)
237. Talpaz, M., "Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis", Leukemia, 35, pp.1~17 (2021)
238. Zhao, Y., "Diverse alterations associated with resistance to KRAS(G12C)inhibition", Nature, 599, pp.679~683 (2021)
239. Proietti, I., "Mechanisms of acquired BRAF inhibitor resistance in melanoma : a systematic review", Cancers, 12, pp.2801~ (2020)
240. Sanchez, J. N., "BRAF and MEK inhibitors : use and resistance in BRAF-mutated cancers", Drugs, 78, pp.549~566 (2018)
241. Welsh, S. J., "Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma", Ther. Adv. Med. Oncol, 7, pp.122~136 (2015)
242. Kun, E., "MEK inhibitor resistance mechanisms and recent developments in combination trials", Cancer Treat. Rev, 92, pp.102137~ (2021)
243. Armaghani, A. J., "Alpelisib in the treatment of breast cancer : a short review on the emerging clinical data", Breast Cancer, 12, pp.251~258 (2020)
244. Wright, S. C. E., "Mechanisms of resistance to PI3K inhibitors in cancer: adaptive responses, drug tolerance and cellular plasticity", Cancers, 13, pp.1538~ (2021)
245. Li, Z., "Mechanisms of CDK4", 6 inhibitor resistance in luminal breast cancer, 2020, pp.11, 580251~
246. Royce, M., "FDA approval summary : abemaciclib with endocrine therapy for high-risk early breast cancer", J. Clin. Oncol, 40, pp.1155~1162 (2022)
247. Awad, M. M., "Acquired resistance to KRAS(G12C)inhibition in cancer", N. Engl. J. Med, 384, pp.2382~2393 (2021)
248. Kaminskas, E., "FDA drug approval summary : azacitidine(5-azacytidine, Vidaza)for injectable suspension", Oncologist, 10, pp.176~182 (2005)
249. Kim, N., "FDA approval summary : decitabine and cedazuridine tablets for myelodysplastic syndromes", Clin. Cancer Res, 28, pp.3411~3416 (2022)
250. Bondarev, A. D., "Recent developments of HDAC inhibitors: emerging indications and novel molecules", Br. J. Clin. Pharmacol, 87, pp.4577~4597 (2021)
251. Fantin, V. R., "Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications", Clin. Cancer Res, 13, pp.7237~7242 (2007)
252. Julia, E., "EZH2 inhibition by tazemetostat : mechanisms of action, safety and efficacy in relapsed", refractory follicular lymphoma, 2021, pp.17, 2127~2140
253. McMurry, H., "IDH inhibitors in AML-promise and pitfalls", Curr. Hematol. Malig. Rep, 16, pp.207~217 (2021)
254. Merin, N. M., "Clinical use of proteasome inhibitors in the treatment of multiple myeloma", Pharmaceuticals, 8, pp.1~20 (2014)
255. Bennett, M. K., "Resistance to Targeted Therapies in Multiple Myeloma", pp.39~59 (2021), Springer International Publishing
256. Yue, X., "Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies", Cancer Cell Int, 20, pp.524~ (2020)
257. Xie, H., "Recent advances in the clinical targeting of hedgehog", GLI signaling in cancer, 2019, pp.8, 394~

관련 논문AI추천